We have not reviewed the charts of United Therapeutics Corporation (UTHR) since Dec. 8, 2017 and then we had a long-term Point and Figure target of $175. Prices finally reached that long-term price target this year.
More from Investing
These recently downgraded names are displaying both quantitative and technical deterioration.
The S&P 500 and DJIA are convenient benchmarks, but they can hurt your returns if you give them too much weight.
Here's what I found most positive about the market as the week closed out.
I like to identify a chart or two with a nice setup into the next week, and OB falls into that category.